{
    "organizations": [],
    "uuid": "e5035349d94326c443307a5f047d20c883b0aa9d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bioverativ-and-sangamo-announce-fd/brief-bioverativ-and-sangamo-announce-fda-acceptance-of-ind-application-for-gene-edited-cell-therapy-bivv003-idUSASC0A2KF",
    "ord_in_thread": 0,
    "title": "BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Sangamo Therapeutics Inc:\n* BIOVERATIV AND SANGAMO ANNOUNCE FDA ACCEPTANCE OF IND APPLICATION FOR GENE-EDITED CELL THERAPY BIVV003 TO TREAT SICKLE CELL DISEASE\n* SANGAMO THERAPEUTICS - IND ENABLES BIOVERATIV TO INITIATE PHASE 1/2 CLINICAL TRIAL TO ASSESS SAFETY OF BIVV003 IN ADULTS WITH SICKLE CELL DISEASE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-16T19:36:00.000+03:00",
    "crawled": "2018-05-17T14:23:38.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "sangamo",
        "therapeutic",
        "inc",
        "bioverativ",
        "sangamo",
        "announce",
        "fda",
        "acceptance",
        "ind",
        "application",
        "cell",
        "therapy",
        "bivv003",
        "treat",
        "sickle",
        "cell",
        "disease",
        "sangamo",
        "therapeutic",
        "ind",
        "enables",
        "bioverativ",
        "initiate",
        "phase",
        "clinical",
        "trial",
        "assess",
        "safety",
        "bivv003",
        "adult",
        "sickle",
        "cell",
        "disease",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}